Stocktoria
Rafael Holdings, Inc. RFL
Rafael Holdings, Inc. (RFL) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $917,000 at a -3328.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.395 |
| Retained earnings / assets | -2.035 |
| EBIT / assets | -0.256 |
| Equity / liabilities | 6.251 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| RFL | Rafael Holdings, Inc. | 3/9 | 0.8 | — | — |
| RLYB | Rallybio Corp | 3/9 | 0.76 | — | — |
| STTK | Shattuck Labs, Inc. | 3/9 | -3.77 | — | — |
| SXTP | 60 DEGREES PHARMACEUTICALS, INC. | 3/9 | — | — | — |
| ONCO | Onconetix, Inc. | 4/9 | — | — | — |
| HYPD | HYPERION DEFI, INC. | 5/9 | -16.62 | — | — |
| DARE | Dare Bioscience, Inc. | 3/9 | — | — | — |
About Rafael Holdings, Inc.
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for the potential treatment of Niemann-Pick Disease Type C1 ("NPC1"), a rare, fatal and progressive genetic disorder; and CPI-613 (devimistat), a stable analog of normally transient, acylated catalytic intermediates of lipoate, which is in phase II of clinical trial. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1A and 1B clinical studies targeting patients with advanced cancers. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrument for Carpal Tunnel syndrome. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
FAQ
Is RFL financially healthy?
Rafael Holdings, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does RFL pay a dividend?
No, Rafael Holdings, Inc. does not currently pay a dividend.
How profitable is RFL?
In FY2025, Rafael Holdings, Inc. had a net margin of -3328.2% and a return on equity of -31.0%.
Is RFL a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Rafael Holdings, Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-07-31. Facts plus Stocktoria's own computed scores — not investment advice.